Cancer epigenetics: From laboratory studies and clinical trials to precision medicine

X Yu, H Zhao, R Wang, Y Chen, X Ouyang, W Li… - Cell Death …, 2024‏ - nature.com
Epigenetic dysregulation is a common feature of a myriad of human diseases, particularly
cancer. Defining the epigenetic defects associated with malignant tumors has become a …

Achieving clinical success with BET inhibitors as anti-cancer agents

T Shorstova, WD Foulkes, M Witcher - British journal of cancer, 2021‏ - nature.com
The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Challenges for assessing replicability in preclinical cancer biology

TM Errington, A Denis, N Perfito, E Iorns, BA Nosek - elife, 2021‏ - elifesciences.org
We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of
preclinical research in cancer biology. The initial aim of the project was to repeat 193 …

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Y Cheng, C He, M Wang, X Ma, F Mo, S Yang… - Signal transduction and …, 2019‏ - nature.com
Epigenetic alternations concern heritable yet reversible changes in histone or DNA
modifications that regulate gene activity beyond the underlying sequence. Epigenetic …

MYC protein interactors in gene transcription and cancer

C Lourenco, D Resetca, C Redel, P Lin… - Nature Reviews …, 2021‏ - nature.com
The transcription factor and oncoprotein MYC is a potent driver of many human cancers and
can regulate numerous biological activities that contribute to tumorigenesis. How a single …

Targeting the epigenetic regulation of antitumour immunity

SJ Hogg, PA Beavis, MA Dawson… - Nature reviews Drug …, 2020‏ - nature.com
Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

[HTML][HTML] MYC as a target for cancer treatment

MJ Duffy, S O'Grady, M Tang, J Crown - Cancer treatment reviews, 2021‏ - Elsevier
The MYC gene which consists of 3 paralogs, C-MYC, N-MYC and L-MYC, is one of the most
frequently deregulated driver genes in human cancer. Because of its high prevalence of …

Transcriptional elongation control in developmental gene expression, aging, and disease

Y Aoi, A Shilatifard - Molecular cell, 2023‏ - cell.com
The elongation stage of transcription by RNA polymerase II (RNA Pol II) is central to the
regulation of gene expression in response to developmental and environmental cues in …

Metabolic reprogramming and epigenetic modifications on the path to cancer

L Sun, H Zhang, P Gao - Protein & cell, 2022‏ - academic.oup.com
Metabolic rewiring and epigenetic remodeling, which are closely linked and reciprocally
regulate each other, are among the well-known cancer hallmarks. Recent evidence …

PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy

JM Kelm, DS Pandey, E Malin, H Kansou, S Arora… - Molecular Cancer, 2023‏ - Springer
Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …